Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

Marie Skłodowska-Curie Action · Running

BREAKthrough Breaking the barrier - An integrated multidisciplinary approach to kill Gram-negative bacteria through existing antibiotics by making their outer membrane permeable

Coordinator
Universite Catholique De Louvain, Belgium
Runs
1 January 2023 to 30 September 2027
Status
Running
EU funding
€2.6m
Total cost
—
Partners
19 organisations in 10 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101072632

What the project is doing

In the project's own words, from its summary on CORDIS.

Antimicrobial resistance, which is caused by multi-drug-resistant bacterial pathogens is a global health emergency. Gram-negative bacteria (GNB) notably hinder effective treatment because of their impermeable outer membrane (OM). Consequently, many standard-of-care (SOC) antibiotics cannot access intracellular targets in GNB. The objective of the BREAKthrough European Training Network (ETN) is to sensitise GNB to these antibiotics by making their OM permeable.

To this end, we will develop inhibitors of three protein machineries that are responsible for OM maintenance. Importantly, many known antibacterial agents have characteristics different from drugs that are directed against targets in mammalian cells. To define better rules for antibacterial drug development a data hub will be created to assemble information on the physico-chemical characteristics of molecules that can pass the OM.To achieve these goals, a multi-disciplinary academic-industrial consortium has been assembled with organic chemists, computational chemists and specialists in high-throughput drug screening, zebrafish infection models, bacterial morphogenesis and the molecular biology of the three targets.

The expected outcomes of the BREAKthrough ETN include (i) the development of new chemical space rules for drugs that need to cross the OM, (ii) the discovery of new inhibitors that interfere with OM maintenance to overcome the insensitivity of Gram-negative pathogenic bacteria towards SOC antibiotics and (iii) providing 10 Early Stage Researchers with scientific, technical, business and transferable skills to become professional drug developers with a keen eye for the hurdles in the development of these drugs in an industrial context.

Who is involved

OrganisationCityCountryRole
Universite Catholique De LouvainLouvain La NeuveBelgiumCoordinator
The University of QueenslandBrisbaneAustraliaAssociatedpartner
SyngulonSeraingBelgiumAssociatedpartner
Accelopment Schweiz AGZurichSwitzerlandAssociatedpartner
F. Hoffmann-La Roche AGBaselSwitzerlandAssociatedpartner
Aicuris Anti-Infective Cures AGWuppertalGermanyParticipant
Abac Therapeutics, SLEsplugues De LlobregatSpainParticipant
Fundacio Institut Catala D'investigacio QuimicaTarragonaSpainParticipant
Fundacion Privada Instituto De Salud Global BarcelonaBarcelonaSpainParticipant
Universitat De BarcelonaBarcelonaSpainAssociatedpartner
Universitat Rovira I VirgiliTarragonaSpainAssociatedpartner
Centre National De La Recherche Scientifique CNRSParisFranceParticipant
Naicons SRLSaronnoItalyParticipant
Universita Degli Studi Di MilanoMilanoItalyParticipant
Stichting Amsterdam UmcAmsterdamNetherlandsParticipant
Stichting VuAmsterdamNetherlandsParticipant
Symeres Netherlands BVNijmegenNetherlandsAssociatedpartner
Univerza V LjubljaniLjubljanaSloveniaParticipant
University of Newcastle Upon TyneNewcastle Upon TyneUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI